Spring Bank Pharmaceuticals is an IND-stage drug discovery company. They specialize in developing a new class of pharmaceuticals called small molecule nucleic acid hybrids. Its most advanced product is SB 9200, a potential breakthrough drug for Hepatitis B and C with antiviral and immune stimulatory activities. Spring Bank has also worked other drug discovery programs for COPD, other viral infections and cancer.